Ajouter aux favoris   Ajouter cette page à mon bookmark --- SOCIAL BOOKMARKING --- Digg Furl del.icio.us Netscape

Introduction
While existing treatment strategies for adult acute leukemia may yield satisfactory remission- induction rates, a major clinical concern is the high rate of disease relapse despite attempts to optimize post-remission consolidation therapy. This is acutely problematic among elderly patients who are frequently unable to tolerate the rigors of more intensive treatment approaches.

Scope
Overview of acute leukemias including epidemiology, etiology, disease classification and prognostic variables.
Current treatment controversies and novel therapies in the developmental pipeline.
Analysis of trial data, marketing factors and commercial potential for key technologies in clinical development.
Stakeholder opinions and interview transcripts based on qualitative interviews with key opinion leaders from the US and Europe.
Highlights
For the innovators of novel and efficacious pharmacotherapy, commercial opportunities within the acute leukemia market are rife. Developers can exploit the high unmet needs that currently prevail in the acute leukemia market by using accelerated approval pathways to expedite market access and drive commercialization

Future drug development approaches will respond to the increased identification of gene mutations and their ensuing proteonomic manifestations. This approach is more likely to address the heterogeneity of acute leukemia and will contribute to the increasing trend of risk-stratified treatment approaches.

Reflecting a greater understanding of disease biology, the enthusiastic pursuit of Flt-3 inhibition in the development of novel acute myeloid leukemia treatment has resulted in already crowded pipeline, with four products challenging for first-to-market status: Cephalon's CEP-701, Novartis' PKC-412, Millennium's MLN518 and Pfizer's SU11248.

Reasons to Purchase
Identify the areas of unmet need and clinical controversy in acute leukemia treatment.
Understand how advancements in acute leukemia prognostication and risk-stratification may shift future treatment paradigms
Assess opportunities and risks for innovative treatments targeting the acute leukemias.

Introduction
While existing treatment strategies for adult acute leukemia may yield satisfactory remission- induction rates, a major clinical concern is the high rate of disease relapse despite attempts to optimize post-remission consolidation therapy. This is acutely problematic among elderly patients who are frequently unable to tolerate the rigors of more intensive treatment approaches.

Scope
Overview of acute leukemias including epidemiology, etiology, disease classification and prognostic variables.
Current treatment controversies and novel therapies in the developmental pipeline.
Analysis of trial data, marketing factors and commercial potential for key technologies in clinical development.
Stakeholder opinions and interview transcripts based on qualitative interviews with key opinion leaders from the US and Europe.
Highlights
For the innovators of novel and efficacious pharmacotherapy, commercial opportunities within the acute leukemia market are rife. Developers can exploit the high unmet needs that currently prevail in the acute leukemia market by using accelerated approval pathways to expedite market access and drive commercialization

Future drug development approaches will respond to the increased identification of gene mutations and their ensuing proteonomic manifestations. This approach is more likely to address the heterogeneity of acute leukemia and will contribute to the increasing trend of risk-stratified treatment approaches.

Reflecting a greater understanding of disease biology, the enthusiastic pursuit of Flt-3 inhibition in the development of novel acute myeloid leukemia treatment has resulted in already crowded pipeline, with four products challenging for first-to-market status: Cephalon's CEP-701, Novartis' PKC-412, Millennium's MLN518 and Pfizer's SU11248.

Reasons to Purchase
Identify the areas of unmet need and clinical controversy in acute leukemia treatment.
Understand how advancements in acute leukemia prognostication and risk-stratification may shift future treatment paradigms
Assess opportunities and risks for innovative treatments targeting the acute leukemias.